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Abstract
Drug-drug interactions (DDIs) constitute an important problem in postmarketing pharmacovigilance and in the
development of new drugs. The effectiveness or toxicity of a medication could be affected by the co-administration of
other drugs that share pharmacokinetic or pharmacodynamic pathways. For this reason, a great effort is being made to
develop new methodologies to detect and assess DDIs. In this article, we present a novel method based on drug interaction
profile fingerprints (IPFs) with successful application to DDI detection. IPFs were generated based on the DrugBank
database, which provided 9,454 well-established DDIs as a primary source of interaction data. The model uses IPFs to
measure the similarity of pairs of drugs and generates new putative DDIs from the non-intersecting interactions of a pair.
We described as part of our analysis the pharmacological and biological effects associated with the putative interactions; for
example, the interaction between haloperidol and dicyclomine can cause increased risk of psychosis and tardive dyskinesia.
First, we evaluated the method through hold-out validation and then by using four independent test sets that did not
overlap with DrugBank. Precision for the test sets ranged from 0.4–0.5 with more than two fold enrichment factor
enhancement. In conclusion, we demonstrated the usefulness of the method in pharmacovigilance as a DDI predictor, and
created a dataset of potential DDIs, highlighting the etiology or pharmacological effect of the DDI, and providing an
exploratory tool to facilitate decision support in DDI detection and patient safety.
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Introduction
Drug-drug interactions (DDIs) are a major cause of morbidity
worldwide and a leading source of treatment inefficacy. For this
reason, DDIs cause great concern in patient safety and pharma-
covigilance. Adverse drug events (ADEs) may occur when drug
combinations target shared metabolical and pharmacological
pathways altering the efficacy and safety profile of the drugs.
Potential DDIs are evaluated for experimental drugs pre-clinically
during development and then monitored by drug safety surveil-
lance programs after they enter the marketplace. The develop-
ment of predictive tools to help study possible DDIs is of great
interest to pharmaceutical companies and regulatory authorities,
such as the United States Food and Drug Administration (FDA)
[1]. These organizations are interested in better methods to detect
and assess drug interactions [2].
Depending on the seriousness of the DDI, different measures
are carried out ranging from the introduction of warnings in drug
labels to the withdrawal of drugs from the market. As an example,
in August 2008 the FDA [1] issued a warning about the possibility
of developing rhabdomyolysis, a condition related to severe muscle
injury, through combination treatment with simvastatin and
amiodarone. In contrast, mibefradil, a calcium channel blocker
approved by the FDA [1] in June 1997, was withdrawn from the
market shortly after due to potential harmful interactions with
drugs that prolong the QT interval [3].
In previous work, we proposed a method that used the DDI
DrugBank database along with molecular similarity for detecting
DDIs [4]. Medicinal chemistry researchers have exploited the
concept of molecular similarity for years [5–12], where the basic
idea is that ‘structurally similar molecules are likely to have
similar biological properties’. Molecular fingerprints, digital
representation of chemical features, are useful representations
for comparing the structural similarity between compounds [10–
13]. The basic idea in the development of a molecular
fingerprint is to represent molecules through a vector that
codifies in different positions the presence/absence of structural
features. However, fingerprints could be designed to codify not
only molecular structure information but also different biological
properties.
Following the concept of predictive models based on adverse
drug event profiles [14–15] and comparing drug pairs through
molecular fingerprints [12], we developed a model to predict
DDIs based on the comparison of, what we call, an interaction
profile fingerprint (IPF). The IPF codifies the known interaction
partners of a given drug as a binary vector of 19s and 09s. Two
different interaction fingerprints can be compared using the
Tanimoto coefficient (TC), a general method for comparing the
similarity of two sets [16]. Our motivating hypothesis is as
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follows: if drug i and drug j are similar according to their
interaction fingerprints, then drug i will interact with the same
drugs as drug j with a probability related to the similarity of
their fingerprints and vice versa. Figure 1 shows how the
interactions of two drugs, oxybutynin and dicyclomine, are
transformed into vectors, which are fingerprints, and then
compared using the TC. The drugs associated with the non-
intersecting interactions are predicted to participate in interac-
tions with a probability proportional to the TC score (see
Figure 1). For example, we predict carbamazepine interactions
with dicyclomine with a probability proportional to 0.78
(Figure 1).
The model we developed combines the interaction profile
similarity information using the DDIs specified in DrugBank to
obtain new DDIs, but data from other sources could also be used.
The model results were validated using Drugs.com [17] and
Drugdex [18] databases as reference standards. We provided in
the Table S1 of the Supporting Information a database with
17,230 DDI candidates predicted by the model along with the
possible biological effects.
Methods
Generation of the Established Drug-drug Interaction
(DDI) Database (Matrix M1)
We collected the database from DrugBank [19] in a previous
publication [4]. Only small approved drugs, not including proteins
and peptides, were introduced in the previous model resulting in
DDI information for 928 drugs and a set of 9,454 unique DDIs.
Although we used the same dataset in the current article,
improvements through future updates in the DrugBank database
or the use of other important sources of DDIs, such as Drugs.com
database, could be beneficial. This step would require an overall
recalculation of the interaction profiles.
We transformed the set of collected DDIs into a 9286928
binary matrix M1 with value of 1 representing an interaction
between two drugs and value of 0 representing no interaction. The
model included information about the pharmacological effect of
the interaction associated with pairs of drugs as part of the process
(e.g, the entry in DrugBank for the DDI between oxybutynin and
triprolidine is: two anticholinergics may cause additive anticho-
linergic effects and enhance their adverse/toxic effects).
Figure 1. Examples of interaction profile fingerprints (IPFs) calculated for the drugs oxybutynin and dicyclomine. The similarity of
both fingerprints is measured through the TC coefficient. The drugs corresponding to the non-intersecting interactions for the pair are assigned the
TC score and form part of the prediction of the model. The effect associated by the interaction is the same as the original interaction source that
generated the prediction.
doi:10.1371/journal.pone.0058321.g001
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Generation of the Interaction Profile Similarity Matrix M2
The interaction profile similarity matrix M2 is calculated in
three steps:
Interaction profile fingerprints (IPFs) calculation. We
represented all the drugs included in the study by IPFs. The
concept of IPFs is similar to molecular structure fingerprints
[16,20]. The basic idea in IPFs is to represent the drug interactions
for a particular drug as a vector codifying the presence of
interactions in specific positions. As an example, in Figure 1 the
interactions between oxybutynin and all other drugs are codified
as different vector positions (33, 46, 103, 202, 223, 414, 645, 725).
Only the positions whose value is 1 are stored in vector-position
notations. This is a very efficient way to represent a sparse binary
matrix. The same process is carried out for the drug dicyclomine
that shares 7 out of 9 unique interactions with oxybutynin (46,
103, 150, 202, 223, 414, 645, 725). The transformation of the
molecules into IPFs facilitates comparison.
Computation of similarity between fingerprints. We
used the Tanimoto coefficient [16], also known as the Jaccard
index, to compute similarities between all the IPFs. The TC
between two fingerprints A and B is defined as the ratio between
the number of features/interactions in the intersection to the
union of both fingerprints:
TC(A,B)~DA\BD=DA|BD
Construction of the matrix M2. We created a matrix so
that the rows and columns represent drugs and each cell represents
the interaction profile similarity based on the TC between the
corresponding pair of drugs. We computed this matrix using the
MOE software [21].
Prediction of New DDIs (Matrix M3)
To calculate the matrix M3 with new predicted interactions, we
multiplied the matrix M1 (Established DDI database matrix) by
the matrix M2 (Interaction profile similarity matrix) (see Figure 2).
It is worth noting that the values in the diagonal of the matrices
M2 and M3 are 0 since the interaction of a drug with itself is not
taken into account. Although the model could generate multiple
scores for the same interaction based on similarities from different
pairs, we only considered the predicted interaction with the
highest TC value. For this reason, in each cell of the product of the
matrices, only the highest value in the array-multiplication is
retained (see Figure 2). We transformed the resulting matrix into
the symmetric matrix M3 considering the highest value (TC) for
each pair of drugs. A set of new predicted DDIs are then generated
from M3, and the biological effect provided by the initial DDI
source in M1 is captured and associated to the new DDIs. As an
example, Figure 1 shows how we used a known interaction
between haloperidol and dicyclomine to predict an interaction
between haloperidol and oxybutynin. In addition, we assigned the
biological effect of the known interaction ‘‘Increased risk of
psychosis and tardive dyskinesia’’ to the predicted interaction.
Evaluation
Hold-out validation. We divided the database randomly in
two sets: training and test sets. We performed two evaluations by
moving 15% and 30% of the initial interactions to the test set, and
by constructing the model with the remaining interactions in the
new matrices M1 and M2. To evaluate the performance in the
training and test sets, we plotted the Receiver Operating
Characteristic (ROC) curves and used the area under this curve
(AUROC) as a summary statistic.
Test evaluation. For the assessment of the performance of
the model we used four different independent test sets, which do
not contain any interactions from the initial DDI database M1: A)
the top 100 DDIs generated by the model according to the TC
value, B) a random set of 100 drug interactions with a TC$0.7, C)
a random set of 100 drug interactions with a TC$0.4, and D) the
interactions generated by the model with a TC$0.4 for the 50
most frequently sold drugs in 2010 [22]. We used the Interaction
Checker from Drugs.com [17] and Drugdex (Micromedex)
database [18] as a reference standard to determine the number
of interactions that were correctly predicted. The level of
documentation in the reference standard ranges from ‘interactions
clearly established through controlled studies’ to ‘limited studies
but the interactions are recognized through pharmacological
knowledge’. We calculated precision and enrichment factor
compared to random selection (see formulas in Table 1) for the
four sets as measurements of the performance. In addition, in
order to provide more information, we plotted a Receiver
Operating Characteristic (ROC) curve for test set D. The
predicted biological/pharmacological effect associated with the
DDIs was also assessed based on the Drugs.com and Drugdex
databases.
Random results evaluation. The results obtained by the
model were compared to random expectations. We created a
random system taking into account the list of 50 most frequently
sold drugs in 2010. The top 50 list included 50 generic drug names
but we only included 41 generic names in the system. Nine of these
drugs are not represented in the DrugBank DDI database. We
cannot generate interaction predictions for these drugs so we
removed them from consideration. These drugs were mometa-
sone, ezetimibe, ferrous fumarate, naloxone, sitagliptin, latano-
prost, insulin glargine, insulin aspart, and omega-3-acid ethyl
esters.
The number of possible interactions for 41 drugs in a matrix of
928 drugs is 37,187 (927 factorial 41 times). We estimated the
number of positive cases as 7,068 interactions found in Drugs.com
and/or Drugdex and used a one-sided Fisher’s exact test to
calculate significance (p-value).
Results
We combined similarity information by means of interaction
profile fingerprint-based modeling with the initial database
containing 928 drugs and 9,454 DDIs, as described in the
Methods section. The final model generated a matrix of 430,128
DDI scores. Among these interactions are the initial 9,454
DrugBank DDIs used to develop the model. We evaluated the
performance of the model through hold-out validation and
external test series.
Hold-out Validation Model Performance
We performed two different evaluations by dividing the initial
database into training and testing subsets. In the first we moved
15% of the interactions from the training to the testing set and in
the second we moved 30%. Using DrugBank DDIs as true
positives we plotted ROC curves and computed the area under the
curve (AUROC). We found an AUROC = 0.967 for the 15%
hold-out and AUROC = 0.963 for the 30% hold-out (Figure 3).
The stability of the model is barely affected even when we
removed twice as many interactions. However, high performance
in these sets is expected since the similarity matrix was generated
using drug interaction profile information where the drugs and
Drug-Drug Interactions Using Interaction Profile
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Figure 2. The model generates interactions through the multiplication of the matrix M1 (Established DDI matrix) by the matrix M2
(Interaction profile similarity matrix. Note that each cell shows the TC between drugs A, B and C but interactions with more drugs are
considered to calculate the TC value). The values in the diagonal of the matrices are set 0 since drug interactions with themselves are not taken into
account. In the final matrix M3 only the maximum value in the multiplication-array in each cell is preserved and a symmetry-based transformation is
Drug-Drug Interactions Using Interaction Profile
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interactions in DrugBank have been specified and form a closed
system. As an example, the interactions retrieved for two drugs
that share all the interactions in the initial database have the
maximum score (TC = 1). For this reason, further evaluation of the
model using independent test sets with no interactions previously
collected in the initial DDI database is a necessary step to prove
the prediction power.
Test Set Model Performance
Test set A. The TOP 100 drug interactions predicted by
the model (TC_threshold = 0.92). We found 50 out of 100
interactions in Drugs.com and/or Drugdex (Micromedex) data-
bases. The precision of this external set is 0.50. Random
expectations (see Methods section) selecting 100 interactions in a
set of 37,187 possible interactions where there are 7,068 positive
cases, would detect 19 positive cases (random precision = 0.19).
The performance of the model showed a 2.6 fold (p,0.001)
enrichment factor (see Table 1 and Table S2).
Test set B. Random set of predicted 100 drug interactions
with a TC$0.7. We found similar results for the second
independent test where 43 out of 100 random interactions with a
TC$0.7 were in the reference standard. The precision in the
second test set is 0.43 and the enrichment factor 2.3 (p,0.001) (see
Table 1 and Table S3).
Test set C. Random set of predicted 100 drug interactions
with a TC$0.4. In the evaluation of the third test, we detected
in our reference standard 45 out of 100 random interactions with a
TC$0.4 (see Table 1 and Table S4 for more details).
Test set D. Interactions predicted for the 50 most
frequently sold drugs in 2010. 46% of the generated
interactions with TC$0.4 were confirmed in the reference
standard. The model presents an enrichment factor of 2.4
(p,0.001) (see Table 1 and Table S5 for a detailed description
of the evaluation). In addition, we plotted the ROC curve taking
into account as true positives all the interactions in the set
confirmed in drugs.com/drugdex (see Figure 4a). The area under
the curve is 0.69. Figure 5 shows the enrichment factor and
precision achieved by the model for each drug. Out of the 50
drugs, we included 41 in the evaluation. Nine drugs were not taken
into account because they were not included in our initial
DrugBank DDI database and the model could not predict any
interaction.
Our method outperforms other commonly used approaches. A
method recently published by our research group based on
molecular structure similarity [4] showed less predictive capacity
(AUROC = 0.668) compared to our model (AUROC = 0.687)
when applied to the test set D (see Figure 4). In addition we tested
if our model could predict pharmacodynamic interactions as well
as pharmacokinetic. Using DrugBank annotations, we identified
and removed any interactions between drugs with shared
metabolism by a cytochrome p450 (CYP) metabolizing enzyme
(1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5 and 3A7) [19].
14,242 interactions in the test set D included in the CYP list were
removed. We found that our approach performed nearly as well
(AUROC = 0.674), but that the performance of the molecular
structure based approach performed was reduced by 3%
(AUROC = 0.636) (Figure 4).
Pharmacological Effect Prediction
A pharmacology expert manually reviewed and compared the
pharmacological effect described in the predicted interactions for
the test sets to the effect found in Drugs.com and Drugdex
databases. The interactions predicted by the model belong to two
categories: some are generated comparing interaction profiles of
pairs of drugs in the same pharmacological class, whereas the
origin of other interactions resides in the comparison of the profile
fingerprints of pairs of drugs that are not in the same class.
For the test set A with the top 100 interactions, 43 out of 50 true
interactions (86%) were confirmed to have the same effect as the
described in our reference standard (see Table S2). We found a
similar result for the test set B (100 interactions with TC$0.7)
where the effect in 36 out of 43 confirmed interactions (84%) was
considered correct (see Table S3 for a detailed description). For
these test sets, the model generated the majority of the reviewed
interactions through the comparison of pairs of drugs catalogued
in the same or similar pharmacological class (48 out of 50 and 38
out of 43 for test A and B respectively). As the TC values decrease
so does our confidence in the predicted effect as these predictions
result from comparing pairs of drugs with different pharmacolog-
ical profiles. In test set C with TC$0.4, the pharmacological effect
was correct for the 66.7% of the interactions, i.e. 30 out of the 45
interactions found in the reference standard (see Table S4). For the
last test set D, we carried out a more challenging evaluation and
only the effect of the interactions generated through the
comparison of pairs of drugs belonging to different pharmacolog-
ical classes was evaluated. Out of the 640 correct DDIs predicted
by the model for test set D, 215 were from comparing drugs
belonging to different pharmacological classes. We reviewed the
pharmacological effect for this set of 215 predicted interactions
carried out retaining the highest TC value. In the example, the initial interactions A–B and A–C (red color) have a TC score of 0.9 in the matrix M3. The
system generated a new predicted interaction between B and C with a TC score of 0.8 (green color).
doi:10.1371/journal.pone.0058321.g002
Table 1. Model performance in the four independent test
sets A, B, C and D along with random results.
Test set model performance
Set A: TOP 100 predicted interactions according to TC value
TP FP Precision EF p-value
50 50 0.50 2.63 ,.001
Set B: 100 predicted interactions randomly selected with TC$0.7
TP FP Precision EF p-value
43 57 0.43 2.26 ,.001
Set C: 100 predicted interactions randomly selected with TC$0.4
TP FP Precision EF p-value
45 55 0.45 2.37 ,.001
Set D: Predicted interactions with TC$0.4 for the TOP 50 drugs sold in 2010
TP FP Precision EF p-value
640 744 0.46 2.43 ,.001
Random system calculated for the TOP 50 drugs sold in 2010
TP FP Precision – –
19 81 0.19
TP = True positives, FP = False positives, Precision = TP/(TP+FP),
EF (Enrichment factor)~
N correct interactions in test set
N interactions in test set
=
N correct interactions in random set
N interactions in random set
doi:10.1371/journal.pone.0058321.t001
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showing a percentage of correct classification of 59% (the effect
was correct in 126 out of 215 cases).
Table 2 describes some example predictions from the test
dataset D (detailed description is provided in Table S6) for which
the model correctly detected interactions comparing drugs of
different pharmacological classes as well as the effect produced by
these interactions. For instance, the model detected that amoxa-
pine, a tetracyclic antidepressant of the dibenzoxazepine family,
has some similarity with the interaction profile of the antibiotic
linezolid (TC = 0.40), and for this reason the model predicted the
interaction escitalopram-amoxapine with a possible serotoninergic
syndrome.
The model also predicted that levofloxacin could interact with
propafenone, fluconazole, ibutilide, ranolazine, saquinavir and
telithromycin with risk of cardiotoxicity and arrhythmias (see
Table 2 and S6). The interactions were corroborated in
Drugs.com database with a similar effect. We predicted other
combinations, such as atazanavir-salmeterol, to cause cardiotox-
icity and arrhythmias.
The model predicted possible hypertensive crisis with the
combination methylphenidate and linezolid. The system generated
the interaction because linezolid has a similar interaction profile as
the monoamine oxidase inhibitor rasagiline (TC = 0.52) and the
interaction methylphenidate-rasagiline was included in the initial
database.
Among other examples, we also detected that the antidiabetic
pioglitazone could interact with the macrolide antibiotic clarith-
romycin, and with the anti-HIV drugs indinavir and nelfinavir
producing and increased effect of pioglitazone (see Table 2 and
S6).
Although all the new DDIs generated by the model have
corresponding predicted biological effects, it is important to take
into account that as the TC value associated with the new
interaction decreases so does the certainty of the associated effect.
Discussion
The desirable and undesirable drug effects in patients are highly
dependent on pharmacokinetic properties, such as absorption,
distribution, metabolism and excretion (ADME), and pharmaco-
Figure 3. ROC curves in the hold-out validation process: a) training set with the 85% of the DrugBank interactions; b) test set with
the 15% of the extracted DrugBank interactions; c) training set with the 70% of the DrugBank interactions; d) test set with the 30%
of the extracted DrugBank interactions.
doi:10.1371/journal.pone.0058321.g003
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dynamic properties, such as interaction with pharmacological
targets. These important processes can be altered by the co-
administration of different drugs at the same time. For this reason,
drug interactions are an important problem in the surveillance of
approved drugs and in the evaluation and development of new
drug candidates. The FDA has shown its concerns to address this
issue, and provides guidance to perform in vitro and in vivo drug
interactions studies during the developmental stage of new drugs
[2,23–24].
A great effort has been made to develop in silico approaches,
focused on the integration of in vitro data, to predict in vivo drug
interactions [23,25]. These models principally focused on meta-
bolic interactions related to CYP enzymes. Other types of
computational models to predict affinity for CYP enzymes based
on molecular descriptors have also been developed [26]. Although
many interactions are produced by the inhibition of metabolizing
enzymes, there are also other possible mechanisms, such as
interactions with transporters or pharmacological targets. Systems
to further analyze pharmacodynamics interactions in vivo have
been also described [27]. Other approaches to predict different
types of DDIs have been recently published [28–29]; some of them
take into account algorithms to detect interactions in adverse event
reports [30], or text mining methods [31]. Our group has also
recently described a large-scale DDI predictor based on molecular
structure similarity to drug pairs [4]. Gottlieb et al. [32] have
recently published a similar interesting large-scale approach to
predict pharmacokinetic and pharmacodynamic DDIs. The
authors used the concept of similarity to drug pairs, including
different measurements, such as chemical structure, drug targets
and side effect similarities, to infer new DDIs in a complex system
with excellent results.
In this article, we developed a novel drug fingerprint based on
drug interactions profile with successful application to DDI
prediction and pharmacovigilance. Through the inclusion of
interaction profile fingerprint-based similarity to the initial well-
established DDI database, we constructed a large-scale drug
Figure 4. ROC curves for test set D: a) ROC curve generated by the IPF model for test set D. Interactions for the top 50 drugs (41 generic
names) confirmed in drugs.com/drugdex were considered as true positives within all the possible interactions in a matrix of 416928 drugs.
Interactions already in the initial DrugBank DDI database (matrix M1) were not included in the analysis; b) ROC showed by a model applied to test D
using MACCS fingerprints; c) ROC curve calculated by the IPF model for test set D but excluding CYP interactions; d) ROC showed by the MACCS
fingerprints model applied to the test D without CYP interactions.
doi:10.1371/journal.pone.0058321.g004
Drug-Drug Interactions Using Interaction Profile
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58321
Figure 5. Enrichment factor (a) and precision (b) achieved by the model regarding random results for top drugs sold in 2010 (test
set D). The test set of drugs are sorted according to the enrichment factor.
doi:10.1371/journal.pone.0058321.g005
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interaction predictor taking into account different pharmacolog-
ical effects caused by pharmacokinetic and pharmacodynamic
characteristics of the drugs implicated in the interaction. The
model generated some predicted interactions comparing the
interaction profiles of pairs of drugs in the same pharmacological
class, whereas a more challenging task is carried out when the
interactions are generated comparing drugs belonging to different
classes. The dataset of DDI candidates is available in the Table S1
of the Supporting Information for further study.
The aim of the model is to detect interactions when two drugs
are implicated and does not account for co-DDIs or secondary
interactions due to primary interactions. The development of a
more complex and challenging model would be necessary to
address this issue. Information about concentration of the drugs
and environmental variables are not included in the model either.
However, implicit bioavailability information has been incorpo-
rated since our initial DDI database contains examples where two
drugs share the same metabolizing enzymes causing a higher
bioavailable doses for one of the drugs implicated in the
interaction.
Targets and drug promiscuity data was not directly introduced
although implicit target information is taken into account since
pharmacodynamic interactions were included in the system. As an
example, Figure 4c has shown that model performance was not
affected after eliminating possible CYP-related DDIs. Neverthe-
less, enhancement in our DDI system could also be achieved
through the integration of metabolizing, transporters and phar-
macological targets information provided by chemical databases
such as PubChem [33]. Pharmacovigilance databases, such as the
FDA’s Adverse Event Reporting System (AERS) [34], or the use of
clinical data in Electronic Health Records (EHR) [35] could be
also combined to further study possible DDI candidates.
Other types of models introducing 2D or 3D molecular
structure data could be integrated in our system. The information
provided by molecular structure can be different or complemen-
tary to IPF fingerprint data. We computed the correlation
coefficient between the TC for all the pairs of drugs in the study
Table 2. Some examples of correct interactions predicted for the 50 most frequently sold drugs in 2010 in which the model
generated interactions through the comparison of drugs belonging to different pharmacological classes.
Similar drug to A1 Predicted interaction DrugA-DrugB Similar drug to B1 TC Predicted effect
Aripiprazole-Nelfinavir Itraconazole 0.55 Increased effect of aripiprazole
Aripiprazole-Atazanavir Ketoconazole 0.45 Increased effect of aripiprazole
Alprazolam Atorvastatin-Digoxin 0.40 Increased effect of digoxin
Midazolam Atorvastatin-Omeprazole 0.51 Increased effect of atorvastatin
Atorvastatin-Miconazole Imatinib 0.43 Increased effect and toxicity of atorvastatin
Buprenorphine-Trospium Triprolidine 0.43 Possible increase adverse/toxic effects due to additivity
Buprenorphine-Trimethobenzamide Triprolidine 0.40 Possible increase adverse/toxic effects due to additivity
Felodipine Conjugated_Estrogens-Oxcarbazepine 0.51 Decreased levels of estrogens
Gefitinib Conjugated_Estrogens-Clarithromycin 0.47 Increased levels/toxicity of estrogens
Nifedipine Conjugated_Estrogens-Cimetidine 0.40 Increased the effect of estrogens
Duloxetine-Tolterodine Tamsulosin 0.59 Possible decreased metabolism and clearance of Tolterodine.
Changes in therapeutic/adverse effects of Tolterodine
Duloxetine-Trimethobenzamide Triprolidine 0.40 Possible increase adverse/toxic effects due to additivity
Duloxetine-Sibutramine Zolmitriptan 0.53 Increased risk of serotonin syndrome
Escitalopram-Amoxapine Linezolid 0.40 Possible serotoninergic syndrome
Eszopiclone-Trimethobenzamide Triprolidine 0.40 Possible increased adverse/toxic effects due to additivity
Ethinyl_Estradiol-Trimipramine Tacrolimus 0.43 Possible increased blood concentration of Trimipramine
Cisapride Levofloxacin-Propafenone 0.44 Increased risk of cardiotoxicity and arrhytmias
Methylphenidate-Linezolid Rasagiline 0.52 Possible hypertensive crisis with this combination
Gefitinib Norethindrone-Voriconazole 0.48 Possible increased serum concentration of norethindrone.
Changes in the therapeutic and adverse effects
Oxycodone-Trospium Triprolidine 0.43 Possible increased adverse/toxic effects due to additivity
Pioglitazone-Nelfinavir Ketoconazole 0.51 Increased the effect of pioglitazone
Dihydro
ergotoxine
Salmeterol-Delavirdine 0.48 Increase salmeterol toxicity
Lidocaine Salmeterol-Atazanavir 0.56 Increased risk of cardiotoxicity and arrhythmias
Sildenafil-Clonidine Terazosin 0.47 Increased risk of hypotension
Simvastatin-Conivaptan Imatinib 0.43 Increased effect and toxicity of statin
Bromazepam Tadalafil-Rifabutin 0.50 Possible decreased serum concentration of Tadalafil. Changes
in the therapeutic and adverse effects
Tadalafil Zolpidem-Doxazosin 0.55 Risk of significant hypotension with this association
TC is the Tanimoto coefficient.
1The similarity between drugs is based on the drug-drug interaction profile.
doi:10.1371/journal.pone.0058321.t002
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using IPF and MACCS fingerprints. The results showed a low
correlation coefficient of 0.167 (see Figure 6). However, it is
noteworthy that there actually is a relationship between molecular
structure similarity and interaction profile information in that if
two drugs share similar interactions it is likely that they have some
structural similarity. It is interesting to note that in the matrix of
9286928 drugs, 2,334 unique pairs were computed with a
TC.0.70 using the structural fingerprints MACCS [36]. Using
our IPFs, 3,332 pairs of drugs were established to have a TC.0.4.
The comparison of both subsets showed 694 pairs of drugs in
common whereas a random measurement would have yielded 18
common cases ( = 333262334/430128). When the structure of
two molecules is compared through classical structural molecular
fingerprints, the TC values are in the range of 0.85 for similar
molecules. However, the TC range for establishing whether two
molecules are similar is highly dependent on the molecular
property information included in the fingerprint. In this article,
TC values of 0.4 still indicate some level of similarity between two
drugs related to interactions, as we show through the evaluation of
the test sets C and D.
The model used only the DDIs described in DrugBank to
generate new predictions. However, we evaluated the model using
a larger set of interactions, such as those in Drugs.com and
Drugdex, which contain many DDIs not described in our initial
DDI database. The limitation in the data used to construct the
model is likely to have influenced the results when using large DDI
databases as a reference standard because DrugBank is a more
limited resource of interactions. This could be an important reason
why there are many cases where the model does not detect the
DDIs described in the reference standard, resulting in false
negative results. For instance, in the evaluation of test D, the
model generated 71 possible interactions with a TC$0.4 for the
three HMG-CoA reductase inhibitors: atorvastatin, rosuvastatin
and simvastatin. However, we found a total of 345 interactions
containing these three drugs in Drugs.com/Drugdex databases
that involved drugs included in our initial DrugBank database.
This fact shows that there are many interactions undetected by our
model when using a TC cutoff of 0.4. Lowering the TC cutoff will
increase the sensitivity of the model but at the same time the false
positive rate will be increased. Improvements in the system could
be made by supplementing the DDIs and drugs in DrugBank with
other sources of drugs and DDI information.
In our evaluation, false positives were deemed to be those that
were not present in the reference standard. However, it is possible
that some of these interactions have not yet been discovered or
that some were not in the reference standard but could have been
found if we used other sources of interactions as a reference
standard. Furthermore, we further studied the false positive DDIs
detected by our method in test set A using the INDI predictor [32]
that provides a large scale state of the art method to predict
pharmacokinetic and pharmacodynamic DDIs. 17 out of 49 DDIs
were also candidates predicted by INDI suggesting agreement
between both systems.
Conclusion
In this article, we have designed a novel molecular fingerprint
based on DDI profiles and developed a useful in silico model to
predict new drug interactions and to specify their possible effects.
The methodology, which can be applied on a large scale, was
systematically validated through the evaluation of independent
and external test sets and showed precision values ranging from
0.4–0.5 with more than two fold enrichment factor enhancement
compared to random expectations. Through this DDI predictor, a
database with 17,230 drug-drug interaction candidates along with
the possible pharmacological effects is provided in the Supporting
Information. This database can be combined with other explor-
atory tools, such as pharmacovigilance data analysis, to facilitate
decision support in DDI detection.
Figure 6. Comparison between the TC for all the pairs of drugs in a matrix of 9286928 using MACCS and IPF fingerprints. The
correlation coefficient (r) calculated through linear regression is 0.167 and p,.0001.
doi:10.1371/journal.pone.0058321.g006
Drug-Drug Interactions Using Interaction Profile
PLOS ONE | www.plosone.org 10 March 2013 | Volume 8 | Issue 3 | e58321
Supporting Information
Table S1 Predicted interactions (not included in the DrugBank
DDI dataset) with a Tanimoto coefficient (TC) score $ 0.4
generated by the model.
(XLSX)
Table S2 Evaluation of the top 100 interactions (test set A).
(XLSX)
Table S3 Evaluation of a random set of 100 interactions with
TC $ 0.7 (test set B).
(XLSX)
Table S4 Evaluation of a random set of 100 interactions with
TC $ 0.4 (test set C).
(XLSX)
Table S5 Interactions predicted by the model with TC $ 0.4
and corroborated in Drugdex and/or Drugs.com databases for the
50 most frequently drugs sold in 2010 (test set D).
(XLSX)
Table S6 Evaluation of the pharmacological effect predicted by
the model for the interactions generated with Tanimoto coefficient
$0.4 for the 50 most frequently sold drugs by unit in 2010.
(XLSX)
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